AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03994744
Drug: PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of Sintilimab (1200mg/3weeks)
Trial: NCT03994744
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).~To reduce GI toxicity, participants start Metformin at 1000 mg daily (500mg am, 500 mg pm) for 1 week.
Trial: NCT00324389
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04944303
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sugammadex is a modified γ-cyclodextrin designed selectively to reverse the effects of the neuromuscular blocking agents (NMBAs) rocuronium and vecuronium
Trial: NCT00232596
Drug: Retigabine
RxNorm normalized name: retigabine
DrugBank: Ezogabine (DB04953)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 7, patients will enter a 12 week maintenance phase
Trial: NCT04325113
Drug: levobupivacaine
RxNorm normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient satisfaction and pain score using a visual anagogic scale (VAS)
Trial: NCT04538365
Drug: Triclosan 0.5 % Topical Solution
RxNorm normalized name: triclosan 0.5 % Topical Solution
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hand antisepsis by scrub Surgical Hand scrubbing using triclosan 0.5% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
Trial: NCT04538365
Drug: propanolol
RxNorm normalized name: Propanolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hand antisepsis by scrub Surgical Hand scrubbing using Propanolol 60% solution both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side
Trial: NCT00813696
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 IV weekly for 7 weeks. Starting at week 9, gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks
Trial: NCT00813696
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m2 IV on days 1, 8, and 15 every 4 weeks
Trial: NCT00947726
Drug: CeraVe
RxNorm normalized name: CeraVe
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Using OTC cream on foot twice daily for two weeks.
Trial: NCT03119623
Drug: sacubitril/valsartan
RxNorm normalized name: SACUBITRIL/VALSARTAN
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sacubitril/valsartan 100mg titrated up to sacubitril/valsartan 200mg
Trial: NCT03119623
Drug: Enalapril
RxNorm normalized name: Enalapril
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: enalapril 5mg, titrated up to 10mg po BID
Trial: NCT01953432
Drug: Doxazosin
RxNorm normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxazosin is initiated at 2 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 4 weeks. Participants will be maintained on 8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
Trial: NCT04331067
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: -Given standard of care
Trial: NCT04331067
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: -Given standard of care
Trial: NCT01115556
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2.0 mg
Trial: NCT01115556
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.5 mg
Trial: NCT02137109
Drug: natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT02648477
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02648477
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02648477
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01914159
Drug: Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monthly intravitreal injections
Trial: NCT04476407
Drug: benapenem
RxNorm normalized name: Benapenem
DrugBank: Benapenem (DB18883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-dose Benapenem 1.0mg(iv), 60min infusion
Trial: NCT04053985
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lenvatinib only
Trial: NCT00126269
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00126269
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01014559
Drug: Oxycodone Naloxone
RxNorm normalized name: naloxone / oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone Naloxone PR Tablet taken twice daily
Trial: NCT01014559
Drug: Oxycodone PR Tablets
RxNorm normalized name: oxycodone Oral Tablet
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone PR Tablets taken twice daily
Trial: NCT01313663
Drug: pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance
Trial: NCT01313663
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pemetrexed IV 500 mg/m2 once every 3 weeks
Trial: NCT02293551
Drug: Lispro
RxNorm normalized name: Lispro PRC
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered SC
Trial: NCT01443572
Drug: desflurane anesthetics
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
Trial: NCT01443572
Drug: sevoflurane anesthetics
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
Trial: NCT02099188
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg/m2 or 33 mg/m2/day or 100 mg/m2 - Concentrate for solution for infusion
Trial: NCT02099188
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 - Concentrate for solution for infusion
Trial: NCT02099188
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg/m2/day - Concentrate for solution for infusion
Trial: NCT02099188
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 mg/m2/day - Concentrate for solution for infusion
Trial: NCT04316039
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concurrent chemotherapy is to receive oral temozolomide, 75 mg/m2 per day, during radiation therapy. Adjuvant chemotherapy will be treated with six cycles of temozolomide, 150 to 200 mg/m2 per day for five consecutive days, repeated every 4 weeks. There is a 28-day break during radiotherapy and adjuvant temozolomide.
Trial: NCT02079636
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally
Trial: NCT02079636
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered IV
Trial: NCT02079636
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV
Trial: NCT02079636
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT02079636
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT02099188
Drug: Adriamycin
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/m2/day - Powder for solution for infusion
Trial: NCT02099188
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3000 mg/m2/day - Powder for solution for infusion
Trial: NCT00006013
Drug: semaxanib
RxNorm normalized name: Semaxanib
DrugBank: Semaxanib (DB06436)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03058224
Drug: Parol 500 mg Tablets (acetaminophen)
RxNorm normalized name: Pazol XS
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic Rescue Medication
Trial: NCT00359736
Drug: sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.
Trial: NCT00689559
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: single dose on day 5
Trial: NCT01275911
Drug: Esmolol
RxNorm normalized name: Esmolol
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction of anesthesia: 1mg/Kg; Maintenance during surgery: 5-15 mcg/kg/min
Trial: NCT00097409
Drug: Ispinesib
RxNorm normalized name: Ispinesib
DrugBank: Ispinesib (DB06188)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01929161
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 International Units
Trial: NCT00622336
Drug: CC-5013
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 25mg daily on Days 1-21 every 28 days.
Trial: NCT00622336
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Lenalidomide 25mg daily on Days 1-21 every 28 days.
Trial: NCT01793688
Drug: Sulbactam Sodium/Ampicillin Sodium
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection or drip infusion. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency)).~Kit for intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection after dissolved in an accompanying reconstitution diluent. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency)).
Trial: NCT03762343
Drug: control group C
RxNorm normalized name: meningococcal group C polysaccharide
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient in this group will receive the intraoperative standard of care(intraoperative intravenous fentanyl and paracetamol)
Trial: NCT03962543
Drug: Mirdametinib (PD-0325901) oral capsule or dispersible tablet
RxNorm normalized name: mirdametinib Oral Capsule
DrugBank: Mirdametinib (DB07101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirdametinib (PD-0325901) capsule or dispersible tablet
Trial: NCT04364113
Drug: Medications needed to maintain low blood pressure
RxNorm normalized name: low-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The MAP goal for the low blood pressure group is \<=92 mm Hg for ages 18-60 and \<=98 for ages 61+. Pharmacological and non-pharmacological therapies will be used to achieve the desired blood pressure values. The recommended anti-hypertensive regimen is a angiotensin-converting-enzyme inhibitor with or without a diuretic agent; a calcium-channel blocker or other medications can be added as needed.
Trial: NCT01758198
Drug: Placebo matching with Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02455609
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02455609
Drug: ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02455609
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03376763
Drug: Abilify maintena
RxNorm normalized name: Abilify Maintena
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Switching from oral atypical antipsychotics to long-acting injectable aripiprazole (Abilify maintena)
Trial: NCT01524783
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants were treated with everolimus 10 mg (two 5 mg tablets) once daily orally taken
Trial: NCT02138838
Drug: Cinacalcet HCl
RxNorm normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules were opened and either sprinkled onto soft food (≥ 5 mg dose) or suspended into a sucrose syrup (≥ 2.5 mg dose) to create a liquid suspension for administration. Tablets were used for doses of 30 mg and higher in participants who could swallow tablets.
Trial: NCT02580474
Drug: Daclatasvir plus Asunaprevir
RxNorm normalized name: asunaprevir
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00733083
Drug: 0,1 mg/kg of oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
Trial: NCT00733083
Drug: Morphine 0,1 mg/kg
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
Trial: NCT00733083
Drug: Dexamethasone 0,5 mg/kg
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: solution for injection, 0,5 mg/kg, one injection in the beginning of anesthesia
Trial: NCT06493656
Drug: 1mL of Triamcinolone (40mg/1mL) Injectable Solution
RxNorm normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mL of Triamcinolone 40mg/1mL solution was included in the injection/hydrodilatation regimen.
Trial: NCT06493656
Drug: 4mL of Lidocaine 1% Solution Injectable Solution
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4mL of 1% Lidocaine solution was included in the injection/hydrodilatation regimen.
Trial: NCT06493656
Drug: 15mL of Normal Saline
RxNorm normalized name: NS-2
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mL of 1% Lidocaine solution was included in the hydrodilatation regimen.
Trial: NCT00948506
Drug: 1% topical cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1% topical cidofovir
Trial: NCT00948506
Drug: 3% topical cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3% topical cidofovir
Trial: NCT04445506
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4mg dexamethasone was given to some patients three times daily for 2 days, 2 times daily for 2 days, once daily for 2 days.
Trial: NCT02832375
Drug: stannous fluoride
RxNorm normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.454% w/w stannous fluoride containing 1100ppm of fluoride
Trial: NCT02832375
Drug: sodium monofluorophosphate
RxNorm normalized name: Sodium Monofluorophosphate
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
Trial: NCT04627532
Drug: PF-07304814
RxNorm normalized name: PF-07304814
DrugBank: PF-07304814 (DB16514)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive PF-07304814
Trial: NCT00477607
Drug: alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplements (1200mg once a day) or placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
Trial: NCT00086541
Drug: Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks
RxNorm normalized name: interferon alfacon-1
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03124199
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin 400 mg/8 h added to the standard triple therapy
Trial: NCT01173055
Drug: milnacipran
RxNorm normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
Trial: NCT05058209
Drug: Triamcinolone acetonide extended-release injectable suspension
RxNorm normalized name: triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zilretta (Triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee OA. The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis (2%), cough (2%), contusions (2%) and joint swelling (3%). For additional details, please see Package Insert (http://www.zilrettalabel.com/PI.pdf). The website for Zilretta additionally lists: joint pain, headache, back pain, sore throat and runny nose, and bruising as common side effects of receiving a Zilretta injection.
Trial: NCT02106325
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV of Ketamine (.25mg/kg)
Trial: NCT02106325
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department
Trial: NCT02740426
Drug: Pirarubicin
RxNorm normalized name: pirarubicin
DrugBank: Pirarubicin (DB11616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of ureteroscopy.
Trial: NCT03467763
Drug: Metformin Extended Release Oral Tablet
RxNorm normalized name: metformin Extended Release Oral Tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin hydrochloride extended release tablets in dosages of 250 mg, 500 mg, 750 mg, and 1,000 mg. Individual encapsulations of metformin will contain dosages of 250 mg or 500 mg.
Trial: NCT05058209
Drug: Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension
RxNorm normalized name: betamethasone acetate / betamethasone sodium phosphate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celestone (betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL) is indicated as an intra-articular injection for the management of chronic or long-term inflammation associated with multiple conditions including severe allergies, dermatological diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system disorders, ophthalmologic diseases, renal diseases, respiratory diseases and rheumatic disorders, and others that may not be listed. Celestone Soluspan is available in generic form. The most commonly reported adverse reactions include acne, increased hunger, and weight gain.